Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma
PDF | HTML | How to cite
Metrics: PDF 1739 views | HTML 2720 views | ?
Se Young Jang1,*, Gyeonghwa Kim2,*, Soo Young Park1, Yu Rim Lee1, Sang Hoon Kwon1, Hyeong Seok Kim1, Jun Sik Yoon1, Jun Seob Lee1, Young-Oh Kweon1, Heon Tak Ha3, Jae Min Chun3, Young Seok Han3, Won Kee Lee4, Jun Young Chang5, Jung Gil Park6, Byungheon Lee2, Won Young Tak1 and Keun Hur2
1Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea
2Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
3Department of Surgery, Kyungpook National University School of Medicine, Daegu, Republic of Korea
4Biostatistics, Medical Research Collaboration Center in Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Republic of Korea
5Department of Neurology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea
6Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea
*These authors contributed equally to this work
Keun Hur, email: [email protected]
Won Young Tak, email: [email protected]
Keywords: hepatocellular carcinoma, long noncoding RNA ATB, survival, prognosis, epithelial mesenchymal transition
Received: June 28, 2017 Accepted: September 04, 2017 Published: September 20, 2017
Hepatocellular carcinoma (HCC) is a worldwide health problem and it is important to understand the mechanistic roles of the biomolecules involved in its pathogenesis. Long non-coding RNAs (lncRNAs) are frequently and aberrantly expressed in various human cancers and are known to play a role in cancer pathogenesis. The aim of this study was to analyze the expression of lncRNA-ATB in HCC and investigate the implications for prognoses.
In total, 100 samples of HCC tissues and their corresponding, adjacent, non-cancerous liver tissues were collected. Total RNAs were extracted and the expression levels of lncRNA-ATB were measured by qRT-PCR. The association of lncRNA expression with clinicopathological features and patient survival were then analyzed.
LncRNA-ATB was significantly upregulated in HCC tissues compared with the levels in corresponding non-cancerous tissues. Expression of lncRNA-ATB was significantly associated with portal vein thrombosis, intrahepatic or extrahepatic metastases, mUICC stage, and the BCLC stage. Large tumors (> 5 cm, HR = 3.851, 95% CI = 1.431–10.364, p = 0.008) and higher lncRNA-ATB expression (HR = 4.158, 95% CI = 1.226–14.107, p = 0.022) were the significant prognostic factors for overall survival.
With this novel evidence of the involvement of lncRNA-ATB in HCC pathogenesis and clinical features, lncRNA-ATB can be concluded to have potential as a biomarker for the prognosis of HCC and as a targeted therapy for afflicted patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.